Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
December 11 2020 - 8:00AM
Galectin Therapeutics Inc. (NASDAQ:GALT), the
leading developer of therapeutics that target galectin proteins,
today announced that Pol F. Boudes, M.D., Chief Medical Officer,
has been invited to make a presentation, entitled “Belapectin, a
Galectin-3 Inhibitor in Phase 2b/3 for the Treatment of NASH
Cirrhosis,” at the 4th Annual Digital NASH Summit. Dr. Boudes will
be speaking at 09:00 AM EST on December 17, 2020.
To register for the 4th Annual NASH Summit, click here:
https://nash-summit.com/get-involved/register/
About Belapectin
(GR-MD-02)Belapectin (GR-MD-02) is a complex carbohydrate
drug that targets galectin-3, a critical protein in the
pathogenesis of fatty liver disease and fibrosis. Galectin-3 plays
a major role in diseases that involve scarring of organs including
fibrotic disorders of the liver, lung, kidney, heart and vascular
system. The drug binds to galectin proteins and disrupts their
function. Preclinical data in animals models have shown that
belapectin has robust treatment effects in reversing
liver fibrosis and cirrhosis. Belapectin results in
the NASH-CX clinical trial, which were published
in Gastroenterology, exhibited a favorable safety profile and
clinically meaningful efficacy results in patients without
esophageal varices at baseline demonstrated by a prevention of
development of varices when compared to placebo; these results
provide the basis for the conduct of the NASH-RX trial. The NASH-RX
trial, entitled “A Seamless Adaptive Phase 2b/3, Double-Blind,
Randomized, Placebo-controlled Multicenter, International Study
Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the
Prevention of Esophageal Varices in NASH Cirrhosis” began enrolling
patients in June 2020 and is posted
on www.clinicaltrials.gov (NCT04365868).
About Fatty Liver
Disease with Advanced Fibrosis and CirrhosisNon-alcoholic
steatohepatitis (NASH) has become a common disease of the liver
with the rise in obesity and other metabolic diseases. NASH is
estimated to affect up to 28 million people in
the U.S. It is characterized by the presence of excess
fat in the liver along with inflammation and hepatocyte damage
(ballooning) in people who consume little or no alcohol. Over time,
patients with NASH can develop excessive fibrosis, or scarring of
the liver, and ultimately liver cirrhosis. It is estimated that as
many as 1 to 2 million individuals in the U.S. will
develop cirrhosis as a result of NASH, for which liver
transplantation is the only curative treatment available.
Approximately 8,890 liver transplants are performed annually in
the U.S. There are no drug therapies approved for the
treatment of liver fibrosis or cirrhosis.
About Galectin TherapeuticsGalectin
Therapeutics is dedicated to developing novel therapies to
improve the lives of patients with chronic liver disease and
cancer. Galectin’s lead drug belapectin (formerly known as
GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3
protein which is directly involved in multiple inflammatory,
fibrotic, and malignant diseases, for which it has Fast Track
designation by the U.S. Food and Drug Administration. The lead
development program is in non-alcoholic steatohepatitis (NASH) with
cirrhosis, the most advanced form of NASH-related fibrosis. This is
the most common liver disease and one of the largest drug
development opportunities available today. Additional development
programs are in treatment of combination immunotherapy for advanced
melanoma and other malignancies. Advancement of these additional
clinical programs is largely dependent on finding a suitable
partner. Galectin seeks to leverage extensive scientific and
development expertise as well as established relationships with
external sources to achieve cost-effective and efficient
development. Additional information is available
at www.galectintherapeutics.com.
Forward Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as “may,”
“estimate,” “could,” “expect” and others. They are based on
management’s current expectations and are subject to factors and
uncertainties that could cause actual results to differ materially
from those described in the statements. These statements include
those regarding the hope that Galectin’s development program for
belapectin will lead to the first therapy for the treatment of
fatty liver disease with cirrhosis and those regarding the hope
that our lead compounds will be successful in cancer immunotherapy
and in other therapeutic indications. Factors that could cause
actual performance to differ materially from those discussed in the
forward-looking statements include, among others, that trial
endpoints required by the FDA may not be achieved; Galectin may not
be successful in developing effective treatments and/or obtaining
the requisite approvals for the use of belapectin or any of its
other drugs in development; the Company may not be successful in
scaling up manufacturing and meeting requirements related to
chemistry, manufacturing and control matters; the Company’s current
NASH-RX clinical trial and any future clinical studies as modified
to meet the requirements of the FDA may not produce positive
results in a timely fashion, if at all, and could require larger
and longer trials, which would be time consuming and costly; plans
regarding development, approval and marketing of any of Galectin’s
drugs are subject to change at any time based on the changing needs
of the Company as determined by management and regulatory agencies;
regardless of the results of any of its development programs,
Galectin may be unsuccessful in developing partnerships with other
companies or raising additional capital that would allow it to
further develop and/or fund any studies or trials. Galectin has
incurred operating losses since inception, and its ability to
successfully develop and market drugs may be impacted by its
ability to manage costs and finance continuing operations. Global
factors such as COVID-19 may limit access to NASH patient
populations around the globe and slow trial enrollment and prolong
the duration of the trial and significantly impact associated costs
as well as impact other trial related activities including, amongst
others, manufacturing and regulatory reviews. For a discussion of
additional factors impacting Galectin’s business, see the Company’s
Annual Report on Form 10-K for the year ended December 31,
2019, and subsequent filings with the SEC. You should not
place undue reliance on forward-looking statements. Although
subsequent events may cause its views to change, management
disclaims any obligation to update forward-looking statements.
Company
Contact:Jack Callicutt, Chief Financial Officer(678)
620-3186ir@galectintherapeutics.com
Galectin
Therapeutics and its associated logo is a registered trademark
of Galectin Therapeutics Inc. Belapectin is the USAN
assigned name for Galectin Therapeutics’ galectin-3 inhibitor
GR-MD-02.
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From May 2024 to Jun 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Jun 2023 to Jun 2024